A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Run by Novo Nordisk A/S · NCT03811561 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-11-07.
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Novo Nordisk A/S Industry-sponsored |
| Drugs / interventions | Semaglutide, Placebo (semaglutide) |
| Locations | 230 sites (Brazil, Bulgaria, Canada, Czechia, Germany, Greece, India, Israel and more) |
| Trial ID | NCT03811561 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, age greater than or equal to 18 years at the time of signing informed consent * Diagnosed with type 2 diabetes mellitus. * HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive). * Eye inclusion criteria (both eyes must meet all criteria): * Early Treatment Diabetic Retinopathy Study (ETDRS) level of 10-75 (both inclusive) evaluated by fundus photography and confirmed by central reading centre * No ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema six months prior to the day of screening. * No anticipated need for ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema within three months after randomisation. * Best-corrected visual acuity greater than or equal to 30 letters using the ETDRS visual acuity protocol * No previous treatment with pan-retinal laser photocoagulation * No substantial non-diabetic ocular condition that, in the opinion of the ophthalmologist, would impact diabetic retinopathy or diabetic macular oedema progression during the trial * No substantial media opacities that would preclude successful imaging Exclusion Criteria: * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening * Subjects presently classified as being in New York Heart Association (NYHA) Class IV * Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR less than 30 ml/min/1.73 m\^2 * Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma * Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods * Concurrent treatment with any GLP-1 receptor agonist or DPP-4 inhibitor from randomisation. * Receipt of any investigational medicinal product within 30 days before screening * Previous participation in this trial. Participation is defined as randomisation * Known or suspected hypersensitivity to trial products or related products * Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
Where it's running
-
Synexus Rsch /Cnt Phnx Med C
Phoenix, Arizona, United States -
Del Sol Research Management, LLC
Tucson, Arizona, United States -
South Arizona VA Healthcare System
Tucson, Arizona, United States -
Synexus Cln Rsrch Inc - Orange Gro FP
Tucson, Arizona, United States -
Southern California Res Ctr
Coronado, California, United States -
Fdrc
Costa Mesa, California, United States
Show 44 more locations
-
Advanced Investigative Medicine, Inc.
Hawthorne, California, United States -
Diabetes/Lipid Mgmt & Res Ctr
Huntington Beach, California, United States -
Scripps Whittier Diabetes Inst
La Jolla, California, United States -
Torrance Clin Res Inst, Inc.
Lomita, California, United States -
Angel City Research, Inc.
Los Angeles, California, United States -
Downtown LA Res Ctr. Inc.
Los Angeles, California, United States -
Riverside University Health System Medical Center
Moreno Valley, California, United States -
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, United States -
Clinical Trials Research_Sacramento_0
Sacramento, California, United States -
UCLA Diabetes Center at Santa Monica
Santa Monica, California, United States -
Coastal Metabolic Research Center
Ventura, California, United States -
Diablo Clinical Research, Inc.
Walnut Creek, California, United States -
Barbara Davis Center
Aurora, Colorado, United States -
Rocky Mount Reg VA Med-DN
Aurora, Colorado, United States -
Chase Medical Research LLC
Waterbury, Connecticut, United States -
Innovative Research of W FL
Clearwater, Florida, United States -
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida, United States -
Reyes Clinical Research, Inc
Miami, Florida, United States -
Renstar Medical Research
Ocala, Florida, United States -
Atlanta Diabetes Associates
Atlanta, Georgia, United States -
Endo Res Solutions Inc
Roswell, Georgia, United States -
Apex Medical Research Inc
Chicago, Illinois, United States -
The University Of Chicago
Chicago, Illinois, United States -
American Health Network of Indiana, LLC_Avon
Avon, Indiana, United States -
American Health Network of Indiana, LLC_Greenfield
Greenfield, Indiana, United States -
Iowa Diab & Endo Res Center
West Des Moines, Iowa, United States -
VA Medical Center
Lexington, Kentucky, United States -
Kentucky Diabetes-Endocrinology Center
Lexington, Kentucky, United States -
The Research Group of Lexington LLC
Lexington, Kentucky, United States -
L-MARC Research Center
Louisville, Kentucky, United States -
Four Rivers Clinical Research Inc
Paducah, Kentucky, United States -
MedStar Hlth Res Institute
Hyattsville, Maryland, United States -
Brigham & Women's Hospital
Boston, Massachusetts, United States -
Boston Medical Center_Cary
Boston, Massachusetts, United States -
Joslin Center For Diabetes
Boston, Massachusetts, United States -
Joslin Diabetes Center
Boston, Massachusetts, United States -
Michigan Medicine
Ann Arbor, Michigan, United States -
Synexus Clinical Research US, Inc._Tempe_0
Richfield, Minnesota, United States -
Diabetes & Endo Specialists Inc
Chesterfield, Missouri, United States -
Palm Research Center Inc-Vegas
Las Vegas, Nevada, United States -
Southern New Hampshire Diabete
Nashua, New Hampshire, United States -
Lovelace Scientific Resources Inc
Albuquerque, New Mexico, United States -
University of New Mexico
Albuquerque, New Mexico, United States -
NYC Research, Inc.
New York, New York, United States
+180 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Clinical Reporting Anchor and Disclosure (1452) — Novo Nordisk A/S
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.